(Q35057356)

6 August 2017

1 reference

title

Cyclooxygenase 2: a molecular target for cancer prevention and treatment (English)

1 reference

6 August 2017

1 reference

Kotha Subbaramaiah

1

1 reference

PubMed ID

12559775

6 August 2017

Andrew J Dannenberg

series ordinal

2

1 reference

6 August 2017

1 February 2003

1 reference

Trends in Pharmacological Sciences

6 August 2017

1 reference

6 August 2017

24

1 reference

6 August 2017

2

1 reference

6 August 2017

96-102

1 reference

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Cyclooxygenases: structural, cellular, and molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Dihydroxy bile acids activate the transcription of cyclooxygenase-2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Inhibition of cyclooxygenase-2 gene expression by p53.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2900043-3

7 January 2021

10.1016/S0165-6147(02)00043-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12559775